Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
A new perspective by researchers from the American Cancer Society and the University of Texas Health Science Center at San Antonio shows the high burden of breast cancer mortality in African American (Black) women versus White women began in the United States in the 1980's.
Genetics and other factors that can determine if a woman is at risk for a recurrence of breast cancer have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Center, providing new research avenues for preventing a new tumor from developing.
A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer, results from a recent clinical trial show.
Gender-affirming hormone therapy could influence the way a person's genes are turned on or off, according to a new study.
Many cases of early prostate cancer are dominated by cells that are slow-growing, often leading to a clinical decision to monitor for progression before initiating treatments that can have adverse side effects.
In this interview, News-Medical talks to Dr. Simon Chowdhury and Laetitia Guilloux about the current state of prostate cancer, it's prevalence, treatment options and its future.
Use of menopausal hormone therapy (MHT, also known as hormone replacement therapy, HRT) is not associated with an increased risk of developing dementia, regardless of hormone type, dose, or duration, concludes a large UK study published by The BMJ.
A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for breast cancer patients when diagnostic dilemmas arise.
Early results from a UCLA-led clinical trial found treating women with estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative early breast cancers with a novel type of anti-hormonal therapy, called an oral selective estrogen receptor degrader (SERD), led to clinically meaningful reductions in tumor activity prior to surgery.
South Australian medical researchers have identified a new way in which prostate cancer cells use glucose to grow and survive, which in turn could be the secret to destroying them.
Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study led by Dr. Amar Kishan, assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA and a researcher at the UCLA Jonsson Comprehensive Cancer Center.
A group of Belgium researchers recently discuss their findings in the journal Microorganisms, which describe the influence of several factors on vaccine-induced immunogenicity.
HIV prevention services will be combined with access to gender-affirming hormonal therapy and peer health navigation to try to reduce the disproportionate percentage of transgender women who are HIV positive in an innovative study led by researchers at The University of Texas Health Science Center at Houston (UTHeath).
A class of drugs that inhibits breast cancer progression when used with hormonal therapy might also boost the effectiveness of immune therapy in cases of recurrent, metastatic breast cancer, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
The hormonal therapies used to treat many breast and prostate cancers raise the risk of a heart attack and stroke, and patients should be monitored regularly and receive treatment to reduce risk and detect problems as they occur.
New research from CU Cancer Center member Scott Cramer, PhD, and his colleagues could help in the treatment of men with certain aggressive types of prostate cancer.
A compound isolated from a fungus growing on the roots of a flowering plant in Morocco shows promise as a powerful opponent of aggressive triple negative breast cancer, scientists say.
Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy.
Researchers at the University of Bern led an international team that has identified a novel vulnerability in advanced prostate cancer that is no longer responding to hormonal therapy.
Results from the PROfound phase III study, funded by AstraZeneca and Merck Sharp & Dohme, open up a much-needed new treatment avenue for the more precise and effective treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed with hormonal therapy.